NASDAQ · Biotechnology

IFRX (IFRX) Stock

$1.84 +6.98% NASDAQ: IFRX Healthcare

Valuation

MetricValue
Price$1.84
Market Cap$132.91M
P/E Ratio-4.16
P/B Ratio2.62
P/S Ratio3300.65
EPS (TTM)$-0.64
52-Week High$2.95
52-Week Low$0.74
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-79.94%
ROA-39.06%
ROCE-117.07%
Gross Margin-246.46%
Operating Margin-1444.45%
Net Margin-1463.04%
Debt/Equity0.02
Current Ratio4.15

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-48.0M$-32.0M$-45.0M$-53.0M$-48.0M
Net Profit$-46.0M$-29.0M$-43.0M$-46.0M$-46.0M
EPS$-1.10$-0.61$-0.78$-0.78$-0.66
Op Margin——-70685.6%-31911.4%-164525.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$125.0M$102.0M$120.0M$76.0M$55.0M
Total Liabilities$20.0M$14.0M$18.0M$15.0M$14.0M
Cash$26.0M$16.0M$13.0M$18.0M$16.0M
Borrowings$1.0M$1.0M$1.0M$1.0M$1.0M

Latest News

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos GlobeNewswire · Jun 30, 2026 Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength? Zacks · Jun 26, 2026 What Do Analysts Say About InflaRx N.V. (IFRX)? Insider Monkey · Jun 10, 2026 Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now Insider Monkey · May 31, 2026 InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline MarketBeat · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-40.0M$-34.0M$-38.0M$-49.0M$-34.0M
Investing Cash Flow$-26.0M$19.0M$-18.0M$52.0M$3.0M
Financing Cash Flow$-3.0M$0$-3.0M$0$0
Net Cash Flow$0$-10.0M$-3.0M$6.0M$0
Free Cash Flow$-40.0M$-34.0M$-38.0M$-49.0M$-34.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-444.76
EV / EBITDA-1.81
FCF Yield-29.88%
Quick Ratio4.16
Interest Coverage—
Return 1Y125.34%
Return 3Y-51.57%
Return 5Y-21.79%

Ownership

Insiders Held2.95%
Institutions Held30.29%
Institutions Float Held31.21%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC7,933,9102026-03-31
683 Capital Management LLC3,315,0002026-03-31
Bank of America Corporation1,975,0002026-03-31
Eversept Partners, LP1,758,5732026-03-31
Morgan Stanley1,175,5762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTV $11.27 -2.68% -2.29 $278.56M 0.00%
ATYR $0.49 +1.19% -0.72 $47.62M 0.00%
CNTB $2.07 -1.67% -2.31 $130.02M 0.00%
CNTX $0.62 +4.47% -6.84 $56.69M 0.00%
IMA $5.69 +1.07% -1.49 $64.18M 0.00%

About IFRX

IFRX is led by CEO Niels C. Riedemann, employs 74 people, headquartered in DE, publicly traded since 2017.

IFRX stock trades at $1.84 with a market capitalization of $132.91M. The stock is valued at a price-to-earnings (P/E) ratio of -4.16, price-to-book of 2.62, price-to-sales of 3300.65. Over the past 52 weeks the stock has ranged between $0.74 and $2.95, and currently trades 37.6% below its 52-week high.

On profitability, IFRX generates a return on equity (ROE) of -79.94%, return on capital employed of -117.07%, an operating margin of -1444.45%, a net profit margin of -1463.04%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides